Overview
MRNA market data
Price History
MRNA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.89 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.28 – $85.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $22.5K · P/B 1.33 · P/S 10.12.
Company news
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?The Motley Fool · Jul 21, 2026, 6:30 PM
Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $67Benzinga · Jul 21, 2026, 12:41 PM
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?The Motley Fool · Jul 20, 2026, 11:30 PM
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various IndexesGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Moderna shares are trading lower. The company announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200 in patients with solid tumors.Benzinga · Jul 16, 2026, 6:53 PM
Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid TumorsBenzinga · Jul 16, 2026, 11:03 AM
Intel Stock Has Doubled, So Why Is JPMorgan Calling It a Top Short?Benzinga · Jul 10, 2026, 2:05 PM
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?The Motley Fool · Jul 10, 2026, 11:00 AM
Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $39Benzinga · Jul 8, 2026, 5:20 PM
8-K filing — Moderna, Inc. (MRNA)SEC EDGAR · Jul 8, 2026, 11:08 AM